nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT07660614 | A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Leal Therapeutics, Inc | This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug), pharmacokinetics (what the body does t... | [
{
"type": "DRUG",
"name": "LTX-002"
},
{
"type": "OTHER",
"name": "Placebo (aCSF)"
}
] | 2026-04-29 | https://clinicaltrials.gov/study/NCT07660614 | [] | [
{
"facility": "University Hospital Schleswig-Holstein, Campus Lübeck",
"city": "Lübeck",
"state": "",
"country": "Germany",
"status": "RECRUITING",
"lat": 53.86893,
"lon": 10.68729
},
{
"facility": "Istituto Neurologico \"Carlo Besta\"",
"city": "Milan",
"state": "",
... | 267-503-4800 | clinical.trials@lealtx.com | null | {
"compound": "LTX-002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06643481 | A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Novartis Pharmaceuticals | This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label ex... | [
{
"type": "BIOLOGICAL",
"name": "VHB937"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2024-10-17 | https://clinicaltrials.gov/study/NCT06643481 | [] | [
{
"facility": "University of California San Diego",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Loma Linda University Health",
"city": "Loma Linda",
"state": "California",
"co... | null | {
"compound": "VHB937",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04849065 | Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Our working hypothesis is that the injection of autologous bone marrow mononuclear cells (BMNC) has a positive effect on the natural loss of motor units and on the increase in the size of the motor unit that occurs in patients with ALS during the evolution of the disease | [
{
"type": "DRUG",
"name": "MNC (Mononuclear cells)"
},
{
"type": "DRUG",
"name": "Placebo / Saline"
}
] | 2021-05-01 | https://clinicaltrials.gov/study/NCT04849065 | [
"neuroinflammation"
] | [
{
"facility": "Hospital Clinico Universitario Virgen de la Arrixaca",
"city": "Murcia",
"state": "",
"country": "Spain",
"status": "",
"lat": 37.98704,
"lon": -1.13004
}
] | 968 36 95 00 | miguelblanquer@um.es | null | {
"compound": "MNC (Mononuclear cells)",
"targeting_mechanism": "Autologous bone marrow mononuclear cells to reduce motor unit loss and support motor neuron function through provision of neuroprotective factors and modulation of neuroinflammation.",
"targeting_mechanism_pmid": "37433768",
"animal_results": "unk... |
NCT03626012 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Biogen | The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-Amyotrophic Lateral Sclerosis (ALS). The secondary objectives of this study are to evaluate the pharmacokinetic profile of BIIB078 and to evaluate the effects of BIIB078 on clinical function. As the first-in... | [
{
"type": "DRUG",
"name": "BIIB078"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2018-09-10 | https://clinicaltrials.gov/study/NCT03626012 | [
"C9orf72"
] | [
{
"facility": "Research Site",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Research Site",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"statu... | null | {
"compound": "BIIB078",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03268603 | Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Mayo Clinic | The purpose of this study is to determine the safety and efficacy of intrathecal treatment delivered to the cerebrospinal fluid (CSF) of mesenchymal stem cells in ALS patients every 3 months for a total of 4 injections over 12 months.
Mesenchymal stem cells (MSCs) are a type of stem cell that can be grown into a numbe... | [
{
"type": "DRUG",
"name": "Autologous Adipose-derived Mesenchymal Stromal Cells"
}
] | 2017-10-10 | https://clinicaltrials.gov/study/NCT03268603 | [] | [
{
"facility": "Mayo Clinic",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": ""... | null | {
"compound": "Autologous Adipose-derived Mesenchymal Stromal Cells",
"targeting_mechanism": "Mesenchymal stem cells differentiate into support cells and produce neuroprotective growth factors and anti-inflammatory cytokines to support degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"anima... | ||
NCT06280079 | Ultra-high-caloric, Fatty Diet in ALS | NA | RECRUITING | INTERVENTIONAL | false | University of Ulm | This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Ultra-high-caloric fatty diet"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2024-06-01 | https://clinicaltrials.gov/study/NCT06280079 | [
"metabolic_dysfunction"
] | [
{
"facility": "RWTH Aachen",
"city": "Aachen",
"state": "",
"country": "Germany",
"status": "NOT_YET_RECRUITING",
"lat": 50.77664,
"lon": 6.08342
},
{
"facility": "Charité Universitätsmedizin Berlin",
"city": "Berlin",
"state": "",
"country": "Germany",
"status": ... | +497311775285 | johannes.dorst@uni-ulm.de | null | {
"compound": "Ultra-high-caloric fatty diet",
"targeting_mechanism": "Compensates for hypermetabolism and weight loss by providing high-caloric nutritional support to offset increased energy expenditure and maintain body weight.",
"targeting_mechanism_pmid": "29706605",
"animal_results": "unknown",
"animal_r... |
NCT06266403 | Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications | NA | RECRUITING | INTERVENTIONAL | false | Penn State University | The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
The question is, What are the effects of communicative interaction on verbal communication in people with ALS?
Participants wil... | [
{
"type": "BEHAVIORAL",
"name": "Structured Communicative Interaction"
},
{
"type": "BEHAVIORAL",
"name": "Clear Speech"
},
{
"type": "BEHAVIORAL",
"name": "Unstructured communicative interaction"
},
{
"type": "BEHAVIORAL",
"name": "Clear Speech Structured Communicative I... | 2024-11-05 | https://clinicaltrials.gov/study/NCT06266403 | [] | [
{
"facility": "Speech Core, Pennsylvania State University",
"city": "University Park",
"state": "Pennsylvania",
"country": "United States",
"status": "RECRUITING",
"lat": 40.80201,
"lon": -77.85639
}
] | 814-867-3373 | ajo150@psu.edu | null | {
"compound": "Structured Communicative Interaction",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06284161 | QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up | NA | RECRUITING | INTERVENTIONAL | false | University Hospital, Clermont-Ferrand | Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Quadriceps Combined Test"
}
] | 2022-06-28 | https://clinicaltrials.gov/study/NCT06284161 | [] | [
{
"facility": "CHU de Clermont-Ferrand",
"city": "Clermont-Ferrand",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 45.77969,
"lon": 3.08682
}
] | +33473754963 | promo_interne_drci@chu-clermontferrand.fr | null | {
"compound": "Quadriceps Combined Test",
"targeting_mechanism": "Uses motor-evoked potentials (MEP) to detect and quantify cortical-spinal motor neuron damage and assess central motor pathway alteration and conduction.",
"targeting_mechanism_pmid": "32676769",
"animal_results": "Dynamic neuromuscular remodelin... |
NCT06450691 | Modeling Amyotrophic Lateral Sclerosis With Fibroblasts | NA | RECRUITING | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy ... | [
{
"type": "PROCEDURE",
"name": "biopsy"
}
] | 2025-08-28 | https://clinicaltrials.gov/study/NCT06450691 | [] | [
{
"facility": "CIC Neurosciences",
"city": "Paris",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 33142162472 | mariadelmar.amador@aphp.fr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Motor neuron degeneration occurs with progressive loss of neuromuscular junctions and denervation in SOD1G93A mouse models, and V1-interneuron connections onto fast motor neurons are lost as disease pro... |
NCT06782724 | Psilocybin Therapy for Psychological Distress in Palliative Patients | PHASE2 | RECRUITING | INTERVENTIONAL | false | University Medical Center Groningen | The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are:
* Can psilocybin therapy safely reduce depressive symp... | [
{
"type": "DRUG",
"name": "Psilocybin therapy"
}
] | 2025-07-01 | https://clinicaltrials.gov/study/NCT06782724 | [
"depression_psychological_distress"
] | [
{
"facility": "National Institute of Mental Health",
"city": "Prague",
"state": "",
"country": "Czechia",
"status": "RECRUITING",
"lat": 50.08804,
"lon": 14.42076
},
{
"facility": "Bispebjerg Hospital",
"city": "Copenhagen",
"state": "",
"country": "Denmark",
"sta... | 050 361 2008 | r.a.schoevers@umcg.nl | null | {
"compound": "Psilocybin therapy",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01650818 | Aerobic Exercise Training in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Fondazione Salvatore Maugeri | The purpose of this study is to compare the safety and the effects of moderate-intensity aerobic endurance training to those of an usual physical therapy intervention on exercise capacity and quality of life in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "OTHER",
"name": "Aerobic exercise training"
},
{
"type": "OTHER",
"name": "Standard physical therapy (Stretching/Range-of-motion)"
}
] | 2012-01 | https://clinicaltrials.gov/study/NCT01650818 | [] | [
{
"facility": "Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno",
"city": "Veruno",
"state": "",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.68887,
"lon": 8.52863
}
] | +39-0322-884723 | fabrizio.pisano@fsm.it | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT07743268 | Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS | PHASE1, PHASE2 | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP. | [
{
"type": "DRUG",
"name": "nL-TARDB-006"
}
] | 2026-02-19 | https://clinicaltrials.gov/study/NCT07743268 | [
"TARDBP"
] | [
{
"facility": "Washington University",
"city": "St Louis",
"state": "Missouri",
"country": "United States",
"status": "",
"lat": 38.62727,
"lon": -90.19789
},
{
"facility": "Columbia University, Irving Medical Center",
"city": "New York",
"state": "New York",
"country... | null | {
"compound": "nL-TARDB-006",
"targeting_mechanism": "Antisense oligonucleotide targeting TARDBP to reduce pathogenic TDP-43 protein expression.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04436510 | HEALEY ALS Platform Trial - Regimen B Verdiperstat | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in participants with ALS. | [
{
"type": "DRUG",
"name": "Matching Placebo"
},
{
"type": "DRUG",
"name": "Verdiperstat"
}
] | 2020-07-28 | https://clinicaltrials.gov/study/NCT04436510 | [
"neuroinflammation"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | null | {
"compound": "Verdiperstat",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07321860 | This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling | PHASE2, PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Gipfel Life Sciences GmbH | Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality. A growing body of translational and clinical evidence implicates neuroinflammation, reactive astro... | [
{
"type": "DRUG",
"name": "Galunisertib + Nerandomilast Combination"
}
] | 2026-06-30 | https://clinicaltrials.gov/study/NCT07321860 | [
"tgf_signaling",
"PDE4"
] | [] | null | {
"compound": "Galunisertib + Nerandomilast",
"targeting_mechanism": "Dual inhibition of TGF-β receptor 1 (ALK5) and phosphodiesterase 4 (PDE4) to reduce TGF-β/SMAD-driven astrocytic and fibrotic signaling in GREM2-positive ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pm... | ||
NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation | PHASE3 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Biogen | The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on... | [
{
"type": "DRUG",
"name": "Tofersen"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-05-17 | https://clinicaltrials.gov/study/NCT04856982 | [
"SOD1"
] | [
{
"facility": "HonorHealth Neurology",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "University of California San Diego Medical Center",
"city": "La Jolla",
"state": "California",
... | null | {
"compound": "Tofersen",
"targeting_mechanism": "Antisense oligonucleotide that reduces mutant superoxide dismutase 1 (SOD1) protein expression.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": "... | ||
NCT03377868 | Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | American University of Beirut Medical Center | Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, devastating, neurodegenerative disease characterized by the loss of cortical, brain stem, and spinal motor neurons. Visual evoked potentials studies in patients with ALS suggest visual pathway involvement. Optic coherence tomography (OCT) is a non-invasive cross-se... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Optic coherence tomography"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Pulmonary function test"
}
] | 2018-01-03 | https://clinicaltrials.gov/study/NCT03377868 | [] | [] | +9611350000 | am132@aub.edu.lb | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT05621213 | Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation | NA | TERMINATED | INTERVENTIONAL | false | AGIR à Dom | Satisfaction of patients with amyotrophic lateral sclerosis under non-invasive ventilation regarding home assisted teleconsultation | [
{
"type": "OTHER",
"name": "Teleconsultation assisted by a physiotherapist or nurse"
}
] | 2023-01-13 | https://clinicaltrials.gov/study/NCT05621213 | [] | [
{
"facility": "CHU Grenoble Alpes",
"city": "Grenoble",
"state": "France",
"country": "France",
"status": "",
"lat": 45.17869,
"lon": 5.71479
},
{
"facility": "CHU Montpellier",
"city": "Montpellier",
"state": "France",
"country": "France",
"status": "",
"lat"... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01746381 | Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode | NA | COMPLETED | INTERVENTIONAL | false | Marta Kaminska | Home non-invasive ventilation (NIV) is the standard-of-care as initial therapy for patients with ALS with worsening symptoms or deteriorating respiratory function, and has been recommended by the American Academy of Neurology (AAN) practice parameter for ALS.
This study will compare the current standard BiST mode of v... | [
{
"type": "DEVICE",
"name": "Non-invasive home ventilation"
}
] | 2014-02 | https://clinicaltrials.gov/study/NCT01746381 | [] | [
{
"facility": "Montreal Chest Institute",
"city": "Montreal",
"state": "Quebec",
"country": "Canada",
"status": "",
"lat": 45.50884,
"lon": -73.58781
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07674667 | FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Trace Neuroscience, Inc. | The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal ... | [
{
"type": "DRUG",
"name": "TRCN-1023"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2026-08-20 | https://clinicaltrials.gov/study/NCT07674667 | [
"UNC13A"
] | [
{
"facility": "TUM Klinikum Rechts der Isar",
"city": "Munich",
"state": "",
"country": "Germany",
"status": "RECRUITING",
"lat": 48.13743,
"lon": 11.57549
},
{
"facility": "University Medical Center Rostock",
"city": "Rostock",
"state": "",
"country": "Germany",
... | +1 415-390-9509 | Clinicaltrials@traceneuro.com | null | {
"compound": "TRCN-1023",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | RECRUITING | INTERVENTIONAL | false | Eli Lilly and Company | Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to ev... | [
{
"type": "DRUG",
"name": "LY4256984"
}
] | 2026-05-14 | https://clinicaltrials.gov/study/NCT07571200 | [] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "NOT_YET_RECRUITING",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "University Hospital - London Health Sciences Centre",
"city": "London",
"state": "",
"country": "Canada",
... | 1-317-615-4559 | LillyTrials@Lilly.com | null | {
"compound": "LY4256984",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04691011 | New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disea... | [
{
"type": "OTHER",
"name": "Muscular MRI"
},
{
"type": "OTHER",
"name": "Electrophysiological exam"
},
{
"type": "OTHER",
"name": "Brain MRI"
},
{
"type": "OTHER",
"name": "Spinal cord MRI"
}
] | 2021-06-16 | https://clinicaltrials.gov/study/NCT04691011 | [] | [
{
"facility": "Shahram Attarian",
"city": "Marseille",
"state": "",
"country": "France",
"status": "",
"lat": 43.29695,
"lon": 5.38107
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04393467 | Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS). | NA | UNKNOWN | INTERVENTIONAL | false | Campus Bio-Medico University | This study aims to evaluate safety and efficacy of tSMS in ALS patients and to obtain preliminary data about the effects of tSMS on cortical excitability.
To this purpose, 40 ALS patients will be recruited and randomized to real or sham tSMS. After at least 3 months follow-up, they will undergo tSMS, daily for 120 min... | [
{
"type": "DEVICE",
"name": "tSMS"
},
{
"type": "DEVICE",
"name": "sham tSMS"
}
] | 2020-05-31 | https://clinicaltrials.gov/study/NCT04393467 | [] | [
{
"facility": "Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS",
"city": "Milan",
"state": "",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.46427,
"lon": 9.18951
},
{
"facility": "Neurology Unit, Campus Biomedico University",
... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03613571 | A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | TERMINATED | INTERVENTIONAL | false | TikoMed AB | This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB. A total of 5 subcutaneous (s.c.) doses will be administered at the study clinic.
The study consists of 10 visits; On... | [
{
"type": "DRUG",
"name": "ILB"
}
] | 2018-08-15 | https://clinicaltrials.gov/study/NCT03613571 | [
"ilb"
] | [
{
"facility": "Sahlgrenska University Hospital",
"city": "Gothenburg",
"state": "",
"country": "Sweden",
"status": "",
"lat": 57.70716,
"lon": 11.96679
}
] | null | {
"compound": "ILB",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02236065 | Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders | NA | COMPLETED | INTERVENTIONAL | false | MinYoung Kim, M.D. | This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for patients with brain injury or neurodegenerative disorders. | [
{
"type": "PROCEDURE",
"name": "Umbilical cord blood therapy"
},
{
"type": "BIOLOGICAL",
"name": "Filgrastim"
}
] | 2014-08 | https://clinicaltrials.gov/study/NCT02236065 | [
"neuroinflammation",
"stem_cell_transplantation"
] | [
{
"facility": "CHA Bundang Medical Center, CHA University",
"city": "Seongnam-si",
"state": "Gyeonggi-do",
"country": "South Korea",
"status": "",
"lat": 37.43861,
"lon": 127.13778
}
] | null | {
"compound": "Umbilical cord blood and Filgrastim",
"targeting_mechanism": "Stem cell therapy modulating neuroinflammation to promote neuroprotection and tissue repair.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"... | ||
NCT06810219 | Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS | NA | RECRUITING | INTERVENTIONAL | false | Cognixion | The goal of this study is refine the usability of a BCI based communication platform.
The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and associated communication... | [
{
"type": "DEVICE",
"name": "Cognixion ONE"
}
] | 2025-01-20 | https://clinicaltrials.gov/study/NCT06810219 | [] | [
{
"facility": "Cognixion",
"city": "Santa Barbara",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 34.42083,
"lon": -119.69819
}
] | 8053200774 | chris@cognixion.com | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | RECRUITING | INTERVENTIONAL | false | Johns Hopkins University | This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | [
{
"type": "DRUG",
"name": "Psilocybin"
}
] | 2025-04-09 | https://clinicaltrials.gov/study/NCT06656702 | [
"psilocybin",
"neuroinflammation"
] | [
{
"facility": "Johns Hopkins Center for Psychedelic and Consciousness Research",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "RECRUITING",
"lat": 39.29038,
"lon": -76.61219
}
] | 410-502-0495 | emosmil1@jhmi.edu | null | {
"compound": "Psilocybin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06844370 | Home Versus Hospital Based NIV Care in MND | NA | RECRUITING | INTERVENTIONAL | false | Papworth Hospital NHS Foundation Trust | Non-invasive ventilation (NIV) is commonly offered to people with Motor Neurone Disease (MND) who have breathing difficulties. It improves their quality of life and can prolong life by 6 months or more. It is initially used at night and typically set up during a hospital admission. By the time that they develop respira... | [
{
"type": "OTHER",
"name": "Non-invasive ventilation"
}
] | 2024-03-06 | https://clinicaltrials.gov/study/NCT06844370 | [] | [
{
"facility": "Royal Paworth Hospital",
"city": "Cambridge",
"state": "",
"country": "United Kingdom",
"status": "RECRUITING",
"lat": 52.2,
"lon": 0.11667
}
] | 01223639619 | dariusz.wozniak@nhs.net | null | {
"compound": "Non-invasive ventilation",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00860951 | P300 Brain Computer Interface Keyboard to Operate Assistive Technology | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Michigan | The purpose of this research is to develop tools enable people who are paralyzed to operate technology and access computers. These tools are called brain computer interfaces (BCIs). BCIs would let a person use brain signals to operate technology. | [
{
"type": "DEVICE",
"name": "Brain Computer Interface Keyboard"
}
] | 2008-09 | https://clinicaltrials.gov/study/NCT00860951 | [] | [
{
"facility": "University of Michigan Direct Brain Interface Project",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
},
{
"facility": "Wadsworth Center",
"city": "Albany",
"state": "New York",
"co... | null | {
"compound": "Brain Computer Interface Keyboard",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04866771 | Remotely Supervised tDCS for Slowing ALS Disease Progression | NA | COMPLETED | INTERVENTIONAL | false | University of Illinois at Chicago | Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool to prime motor function in several neu... | [
{
"type": "OTHER",
"name": "Transcranial Direct Current Stimulation (tDCS)"
},
{
"type": "OTHER",
"name": "Sham tDCS + anodal tDCS"
}
] | 2021-08-27 | https://clinicaltrials.gov/study/NCT04866771 | [] | [
{
"facility": "Brain Plasticity Lab",
"city": "Chicago",
"state": "Illinois",
"country": "United States",
"status": "",
"lat": 41.85003,
"lon": -87.65005
}
] | null | {
"compound": "Transcranial Direct Current Stimulation (tDCS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07473765 | Virtual Reality for Anxiety Management in Persons With Amyotrophic Lateral Sclerosis | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Horizon Health Network | Virtual Reality (VR) is gaining traction as a new and innovative leisure to augment healthcare services. Several benefits of the leisure experience, such as distraction and full sensory immersion, have demonstrated a potential to significantly impact the field of healthcare through pain reduction, anxiety reduction, an... | [
{
"type": "BEHAVIORAL",
"name": "Virtual Reality Guided Breathing Exercise"
}
] | 2026-04-01 | https://clinicaltrials.gov/study/NCT07473765 | [] | [] | 506-447-4379 | shane.a.mccullum@horizonnb.ca | null | {
"compound": "Virtual Reality Guided Breathing Exercise",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT01640067 | Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Azienda Ospedaliera Santa Maria, Terni, Italy | Primary aim of the trial
1. to verify safety and tolerability of expanded human fetal neural stem cells
2. to verify safety and tolerability of a microsurgery human fetal neural stem cells transplantation model
3. to recognize each change in patient's quality of life
Secondary aim of the trial
1. assessment of the i... | [
{
"type": "BIOLOGICAL",
"name": "Human Neural Stem Cells"
}
] | 2011-12 | https://clinicaltrials.gov/study/NCT01640067 | [
"neural_stem_cell_transplantation"
] | [
{
"facility": "Azienda Ospedaliera Santa Maria",
"city": "Terni",
"state": "Terni",
"country": "Italy",
"status": "",
"lat": 42.56335,
"lon": 12.64329
}
] | null | {
"compound": "Human Neural Stem Cells",
"targeting_mechanism": "Neural stem cells differentiate into support cells such as astrocytes, oligodendrocytes, or microglia that produce growth factors and anti-inflammatory cytokines to support degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"ani... | ||
NCT07454733 | Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers? | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Trustees of Dartmouth College | Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC). In these multidisciplinary clinics, which occur every 3 to 4 months, people with ALS see up to 12 different healt... | [
{
"type": "BEHAVIORAL",
"name": "Video recording"
},
{
"type": "BEHAVIORAL",
"name": "Notes Instruction"
}
] | 2026-06-01 | https://clinicaltrials.gov/study/NCT07454733 | [] | [
{
"facility": "Mayo Clinic Scottsdale",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "Mayo Clinic Jacksonville",
"city": "Jacksonville",
"state": "Florida",
"country": "United S... | 603-646-7016 | paul.j.barr@dartmouth.edu | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT07410806 | HEALEY ALS Platform Trial - Regimen I NUZ-001 | PHASE2, PHASE3 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS. | [
{
"type": "DRUG",
"name": "NUZ-001"
},
{
"type": "DRUG",
"name": "Matching placebo"
}
] | 2026-02-25 | https://clinicaltrials.gov/study/NCT07410806 | [
"nuz_001"
] | [
{
"facility": "Healey Center for ALS at Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | null | {
"compound": "NUZ-001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04820478 | Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | University of Ulm | Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). One potential mechanism of weight loss in ALS is a disturbance of the mitochondrial complex I which causes an energy deficit in affected cells. Over the last years, various interventional studies targeting the energy deficit in AL... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Beta Hydroxybutyrate Ester (KetoneAid KE4)"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Placebo"
}
] | 2022-04-01 | https://clinicaltrials.gov/study/NCT04820478 | [
"mitochondrial_complex_i"
] | [
{
"facility": "University of Ulm",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
}
] | null | {
"compound": "Beta Hydroxybutyrate Ester (KetoneAid KE4)",
"targeting_mechanism": "Beta hydroxybutyrate ester provides an alternative energy substrate to address mitochondrial complex I dysfunction and energy deficit in ALS cells.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results... | ||
NCT05053035 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | PHASE2 | TERMINATED | INTERVENTIONAL | false | Alector Inc. | A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS. | [
{
"type": "DRUG",
"name": "AL001"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-09-02 | https://clinicaltrials.gov/study/NCT05053035 | [
"C9orf72"
] | [
{
"facility": "University of South Florida",
"city": "Tampa",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 27.94752,
"lon": -82.45843
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "Uni... | null | {
"compound": "AL001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05107349 | Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS) | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Amyotrophic lateral sclerosis (ALS), is a rapidly progressive neurodegenerative disorder, usually leading to death from respiratory failure in 3-5 years. Riluzole, the only drug currently available, only modestly prolongs survival and does not improve muscle strength or function. In ALS, loss of functional motor neuron... | [
{
"type": "PROCEDURE",
"name": "Muscle biopsy"
}
] | 2022-12-12 | https://clinicaltrials.gov/study/NCT05107349 | [] | [
{
"facility": "Pitié-Salpêtrière Hospital",
"city": "Paris",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 0142162467 | nathalie.cormand@aphp.fr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00877604 | Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | The preclinical rationale for tauroursodeoxycholic acid (TUDCA) use in treating patients with amyotrophic lateral sclerosis (ALS) stems from the demonstration of antioxidant, antiapoptotic and neuroprotective properties of TUDCA in the central nervous system (CNS), both in vitro and in vivo models.
This protocol is me... | [
{
"type": "DRUG",
"name": "tauroursodeoxycholic acid (TUDCA)"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2008-06 | https://clinicaltrials.gov/study/NCT00877604 | [
"oxidative_stress",
"apoptosis"
] | [
{
"facility": "Fondazione IRCCS Istituto neurologico Carlo Besta",
"city": "Milan",
"state": "Milan",
"country": "Italy",
"status": "",
"lat": 45.46427,
"lon": 9.18951
}
] | null | {
"compound": "tauroursodeoxycholic acid (TUDCA)",
"targeting_mechanism": "Antioxidant, antiapoptotic and neuroprotective agent acting in the central nervous system",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid... | ||
NCT07636538 | Auto-calibrating System for Upper Limb Disability Assessment, Neurological and Occupational Rehabilitation | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | University of Pavia | This interventional, multicenter, low-intervention clinical trial aims to evaluate the usability, feasibility, safety, and preliminary clinical impact of a robotic rehabilitation system designed for upper limb rehabilitation in adults with neurological disorders, including Parkinson's disease (PD), Amyotrophic Lateral ... | [
{
"type": "DEVICE",
"name": "Auto-calibrating System for Upper Limb disability Assessment, neurological and occupational Rehabilitation"
},
{
"type": "OTHER",
"name": "conventional therapy"
}
] | 2026-06 | https://clinicaltrials.gov/study/NCT07636538 | [] | [] | +393348941743 | cira.fundaro@icsmaugeri.it | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04293484 | Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor ... | [
{
"type": "DEVICE",
"name": "Anodal bilateral motor cortex and cathodal spinal tDCS"
},
{
"type": "DEVICE",
"name": "Sham bilateral motor cortex and sham spinal tDCS"
}
] | 2018-03-12 | https://clinicaltrials.gov/study/NCT04293484 | [
"motor_cortex_stimulation"
] | [
{
"facility": "AO Spedali Civili",
"city": "Brescia",
"state": "BS",
"country": "Italy",
"status": "",
"lat": 45.53558,
"lon": 10.21472
}
] | null | {
"compound": "Transcranial direct current stimulation (tDCS)",
"targeting_mechanism": "Non-invasive neuromodulation technique that applies direct electrical current to the motor cortex and spinal cord to modulate neural activity",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_p... | ||
NCT03280056 | Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients | PHASE3 | COMPLETED | INTERVENTIONAL | false | Brainstorm-Cell Therapeutics | This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotroph... | [
{
"type": "BIOLOGICAL",
"name": "NurOwn® (MSC-NTF cells)"
},
{
"type": "OTHER",
"name": "Placebo"
},
{
"type": "OTHER",
"name": "Bone Marrow aspiration"
}
] | 2017-08-28 | https://clinicaltrials.gov/study/NCT03280056 | [
"neurotrophic_factors"
] | [
{
"facility": "University of California Irvine Alpha Stem Cell Clinic",
"city": "Irvine",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.66946,
"lon": -117.82311
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "C... | null | {
"compound": "NurOwn® (MSC-NTF cells)",
"targeting_mechanism": "Autologous bone marrow-derived mesenchymal stromal cells engineered to secrete neurotrophic factors that provide neuroprotective support to degenerating motor neurons",
"targeting_mechanism_pmid": "",
"animal_results": "Stem cell therapy in precli... | ||
NCT00560287 | Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis | PHASE4 | UNKNOWN | INTERVENTIONAL | false | Fondazione Salvatore Maugeri | Non-invasive mechanical ventilation (NIV) has been increasingly used as a treatment of chronic hypercapnic respiratory failure. Its use in patients affected by chronic obstructive pulmonary disorders is still controversial, while most of the studies performed in restrictive thoracic disorders (RTD), and in particular i... | [
{
"type": "DEVICE",
"name": "Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers"
},
{
"type": "DEVICE",
"name": "Non invasive ventilation"
}
] | 2008-01 | https://clinicaltrials.gov/study/NCT00560287 | [] | [
{
"facility": "Fondazione S.Maugeri",
"city": "Pavia",
"state": "",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.19205,
"lon": 9.15917
},
{
"facility": "Respiratory Unit FSM",
"city": "Pavia",
"state": "",
"country": "Italy",
"status": "NOT_YET_RECRUITING... | 0382 592 | snava@fsm.it | null | {
"compound": "unknown",
"targeting_mechanism": "Non-invasive mechanical ventilation maintains adequate ventilation and alleviates symptoms of chronic hypoventilation in ALS patients with respiratory failure.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurpos... |
NCT02166944 | Tamoxifen Treatment in Patients With Motor Neuron Disease | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Taipei Medical University Shuang Ho Hospital | The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS, and TDP43 can be degraded either by proteasome... | [
{
"type": "DRUG",
"name": "tamoxifen 40 mg daily for one year"
}
] | 2014-04 | https://clinicaltrials.gov/study/NCT02166944 | [
"TARDBP",
"MTOR"
] | [
{
"facility": "Po-Chih Chen",
"city": "New Taipei City",
"state": "",
"country": "Taiwan",
"status": "",
"lat": 25.06199,
"lon": 121.45703
}
] | null | {
"compound": "tamoxifen",
"targeting_mechanism": "Tamoxifen activates autophagy through mTOR inhibition to promote degradation of ubiquitinated or phosphorylated TDP-43 and ameliorate TDP-43 accumulation in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "TDP-43 transgenic mouse models show ... | ||
NCT02306590 | Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University of Ulm | The primary objective of the trial is to investigate the survival time (the time from randomization until death or date of end of the study) compared between control group and experimental group.
This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind trial comparing placebo with high ... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Calogen"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Placebo"
}
] | 2015-02 | https://clinicaltrials.gov/study/NCT02306590 | [] | [
{
"facility": "Department of Neurology, University of Ulm",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
},
{
"facility": "Department of Neurology, University of Wuerzburg",
"city": "Würzburg",
"state": "... | null | {
"compound": "Calogen",
"targeting_mechanism": "High-calorie, high-lipid nutritional supplementation to provide enhanced energy support as add-on therapy in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from... | ||
NCT01051882 | Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Brainstorm-Cell Therapeutics | The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible treatment for patients with Amyotrophic Lateral Sclerosis (ALS) at the early and progressive d... | [
{
"type": "BIOLOGICAL",
"name": "MSC-NTF cells transplantation (IM)"
},
{
"type": "BIOLOGICAL",
"name": "MSC-NTF cells transplantation (IT)"
}
] | 2011-06 | https://clinicaltrials.gov/study/NCT01051882 | [
"neurotrophic_factors"
] | [
{
"facility": "Hadassah Medical Organization",
"city": "Jerusalem",
"state": "",
"country": "Israel",
"status": "",
"lat": 31.76904,
"lon": 35.21633
}
] | null | {
"compound": "MSC-NTF cells",
"targeting_mechanism": "Autologous mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF) support motor neuron survival through trophic support and anti-inflammatory effects.",
"targeting_mechanism_pmid": "34890069",
"animal_results": "SOD1G93A transgenic m... | ||
NCT06429059 | ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments | PHASE2 | COMPLETED | INTERVENTIONAL | false | Duke University | GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy \& axonal transport, and mitochondrial dysfunction. Once a disease category is established, pa... | [
{
"type": "DRUG",
"name": "Astaxanthin"
},
{
"type": "DRUG",
"name": "Protandim"
},
{
"type": "DRUG",
"name": "Melatonin"
},
{
"type": "DRUG",
"name": "MitoQ"
}
] | 2024-06-12 | https://clinicaltrials.gov/study/NCT06429059 | [
"neuroinflammation",
"oxidative_stress",
"autophagy_impairment",
"axonal_transport_defect",
"mitochondrial_dysfunction"
] | [
{
"facility": "Duke University Medical Center",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
},
{
"facility": "Temple University",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "... | null | {
"compound": "Astaxanthin, Protandim, Melatonin, MitoQ",
"targeting_mechanism": "Personalized supplement therapy targeting specific disease pathways: Astaxanthin and Melatonin target oxidative stress; Protandim targets antioxidant systems; MitoQ targets mitochondrial dysfunction to slow ALS progression.",
"targe... | ||
NCT05340660 | mGluR5 Imaging in ALS Using PET | NA | UNKNOWN | INTERVENTIONAL | false | Nathalie Braun | In ALS models, it was shown that receptors, that bind an important messenger substance (glutamate) in the brain, are increased. In this research project, the investigators want to use a specific radioactive substance to find out whether these receptors are more detectable in people with ALS than in healthy people and i... | [
{
"type": "RADIATION",
"name": "[ 18 F]PSS232"
}
] | 2022-04 | https://clinicaltrials.gov/study/NCT05340660 | [
"GRM5",
"glutamate_excitotoxicity"
] | [
{
"facility": "Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen",
"city": "Sankt Gallen",
"state": "",
"country": "Switzerland",
"status": "RECRUITING",
"lat": 47.42391,
"lon": 9.37477
}
] | +41 71 494 35 81 | nathalie.braun@kssg.ch | null | {
"compound": "unknown",
"targeting_mechanism": "mGluR5 imaging to detect increased glutamate receptor levels in ALS",
"targeting_mechanism_pmid": "",
"animal_results": "In ALS models, mGluR5 receptors that bind glutamate are increased.",
"animal_results_pmid": "37895110",
"repurposed_from": "not repurposed... |
NCT03604822 | Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS | NA | UNKNOWN | INTERVENTIONAL | false | Alisa Apreleva | This study evaluates potential of music therapy treatment to support breathing, speech, swallow and cough of persons with amyotrophic lateral sclerosis (ALS). Music therapy is the clinical use of music and its elements to enhance human health and wellbeing. Application of music therapy principles in neurorehabilitation... | [
{
"type": "PROCEDURE",
"name": "Music therapy"
}
] | 2017-09-27 | https://clinicaltrials.gov/study/NCT03604822 | [] | [
{
"facility": "ALS Moscow Centre",
"city": "Moscow",
"state": "",
"country": "Russia",
"status": "",
"lat": 55.75204,
"lon": 37.61781
},
{
"facility": "Cambridge Institute for Music Therapy Research (CIMTR)",
"city": "Cambridge",
"state": "Cambridgeshire",
"country": ... | null | {
"compound": "unknown",
"targeting_mechanism": "Music therapy principles applied in neurorehabilitation to treat motor dysfunctions via cognitive and sensory engagement",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurpos... | ||
NCT01363882 | Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) | NA | TERMINATED | INTERVENTIONAL | false | Columbia University | Use of noninvasive ventilation (NIV, also known colloquially as "Bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival. NIV is typically applied during sleep, and without the benefit of sleep study to determine the optimal settings. The investigators have shown... | [
{
"type": "OTHER",
"name": "Sleep study-guided adjustment of NIV"
},
{
"type": "OTHER",
"name": "Standard initiation of NIV"
}
] | 2008-02 | https://clinicaltrials.gov/study/NCT01363882 | [] | [
{
"facility": "Columbia University Medical Center",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "Sleep study-guided adjustment of noninvasive ventilation (NIV) to optimize nocturnal oxygenation and ventilation",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_... | ||
NCT02496767 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year | PHASE3 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS. | [
{
"type": "DRUG",
"name": "Tirasemtiv"
},
{
"type": "DRUG",
"name": "Placebo tablets"
}
] | 2015-09-03 | https://clinicaltrials.gov/study/NCT02496767 | [
"ACTA1"
] | [
{
"facility": "St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego",
"city": "La Jolla",
... | null | {
"compound": "Tirasemtiv",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05742828 | Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Wake Forest University Health Sciences | A literature review was completed related to the topic of use of the Virtual Seating Coach (VSC) device with clients with Amyotrophic Lateral Sclerosis (ALS) with no results. The VSC components are FDA approved and Health Insurance Portability and Accountability Act (HIPPA) compliant, which have been used for many year... | [
{
"type": "BEHAVIORAL",
"name": "Virtual Seating Coach"
}
] | 2017-09-20 | https://clinicaltrials.gov/study/NCT05742828 | [] | [
{
"facility": "Atrium Health - Neurosciences Institute",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.22709,
"lon": -80.84313
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "Virtual Seating Coach (VSC) device to optimize power wheelchair seating positioning and repositioning",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00580593 | Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | University of Michigan | The goal of this trial is to determine the feasibility of conducting a randomized, double-blind, placebo-controlled trial of nocturnal noninvasive positive pressure ventilation in persons with amyotrophic lateral sclerosis with an forced vital capacity greater than or equal to 50 percent. | [
{
"type": "DEVICE",
"name": "BiPAP® S/T System"
},
{
"type": "OTHER",
"name": "sham-NIPPV"
}
] | 2007-04 | https://clinicaltrials.gov/study/NCT00580593 | [] | [
{
"facility": "University of Michigan",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "Noninvasive positive pressure ventilation (BiPAP) aims to support respiratory function in ALS patients with compromised respiratory muscles.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repu... | ||
NCT03545451 | Neurofeedback Rehabilitation Based on Motor Imaging in Patients in the Immobilization Phase | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | As the prevalence of motor impairment increases with age, the proportion of the population affected by physical limitations is likely to increase in the coming years, considering that one in three people will be over 60 in 2050 (compared to one in five in 2005, INSEE projections). The possibility of reducing recovery t... | [
{
"type": "DEVICE",
"name": "Videogames"
}
] | 2018-10-03 | https://clinicaltrials.gov/study/NCT03545451 | [] | [
{
"facility": "Hopital PITIE SALPETRIERE",
"city": "Paris",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 01 42 16 57 72 | jean-christophe.corvol@aphp.fr | null | {
"compound": "unknown",
"targeting_mechanism": "Videogame-based neurofeedback rehabilitation using motor imaging to enhance motor recovery and motor function.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pm... |
NCT01945853 | Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) | NA | WITHDRAWN | INTERVENTIONAL | false | Johns Hopkins University | This is a pilot study to identify the degree of grey and white matter involvement in patients with Amyotrophic Lateral Sclerosis (ALS) utilizing non-invasive techniques. The imaging to be utilized will be the 7 Tesla (7T) magnetic resonance imaging (MRI) of the brain. These results will be correlated to the ALS Functio... | [
{
"type": "DEVICE",
"name": "7 Tesla MRI"
}
] | 2013-07 | https://clinicaltrials.gov/study/NCT01945853 | [] | [
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "7 Tesla MRI is a non-invasive imaging technique used to identify grey and white matter involvement in ALS and assess changes predictive of disability.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from":... | ||
NCT01083667 | SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Weill Medical College of Cornell University | The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "Pyrimethamine"
}
] | 2009-11 | https://clinicaltrials.gov/study/NCT01083667 | [
"SOD1"
] | [
{
"facility": "Weill Cornell Medical Center/New York Presbyterian Hospital",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
},
{
"facility": "Methodist Neurological Institute",
"city": "Houston",
"state... | null | {
"compound": "Pyrimethamine",
"targeting_mechanism": "Pyrimethamine inhibits SOD1 protein levels in familial ALS.",
"targeting_mechanism_pmid": "29751510",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06172621 | Spinal Cord Associative Plasticity for ALS | NA | RECRUITING | INTERVENTIONAL | false | VA Office of Research and Development | Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS).
The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people with ALS.
The curren... | [
{
"type": "PROCEDURE",
"name": "Spinal Cord Associative Plasticity (SCAP)"
},
{
"type": "PROCEDURE",
"name": "Upper extremity task-oriented exercise"
}
] | 2024-04-01 | https://clinicaltrials.gov/study/NCT06172621 | [
"motor_circuit_plasticity"
] | [
{
"facility": "James J. Peters VA Medical Center, Bronx, NY",
"city": "The Bronx",
"state": "New York",
"country": "United States",
"status": "RECRUITING",
"lat": 40.84985,
"lon": -73.86641
}
] | (718) 584-9000 | francisco.castano@va.gov | null | {
"compound": "unknown",
"targeting_mechanism": "Spinal cord associative plasticity (SCAP) uses synchronized stimulation over the brain and cervical spinal cord to strengthen weakened nerve circuits between the brain and hand muscles.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_resu... |
NCT03359538 | Rapamycin Treatment for ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Azienda Ospedaliero-Universitaria di Modena | In the last years research has pointed out potential mechanisms of pathogenesis in ALS including lack of degradation of abnormally accumulated proteins inside motor neurons, and an unbalanced function of the immune system leading to the prevalence of a neurotoxic function over neuroprotection. These two mechanisms cont... | [
{
"type": "DRUG",
"name": "Rapamycin"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2017-09-19 | https://clinicaltrials.gov/study/NCT03359538 | [
"MTOR",
"autophagy_impairment",
"neuroinflammation"
] | [
{
"facility": "Centro Sla, Irccs A.O.U. S.Martino Ist, Genova",
"city": "Genova",
"state": "",
"country": "Italy",
"status": "",
"lat": 45.21604,
"lon": 11.87211
},
{
"facility": "Centro Clinico Nemo, Fondazione Serena Onlus, Milano",
"city": "Milan",
"state": "",
"co... | null | {
"compound": "Rapamycin",
"targeting_mechanism": "Rapamycin activates autophagy to enhance degradation of abnormally accumulated proteins and modulates immune function to restore neuroprotection over neurotoxic inflammation in ALS.",
"targeting_mechanism_pmid": "34057020",
"animal_results": "unknown",
"anima... | ||
NCT00244244 | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | CytRx | The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured. | [
{
"type": "DRUG",
"name": "arimoclomol"
}
] | 2005-10 | https://clinicaltrials.gov/study/NCT00244244 | [
"heat_shock_response"
] | [
{
"facility": "University of California, Irvine Medical Center",
"city": "Irvine",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.66946,
"lon": -117.82311
},
{
"facility": "University of Miami School of Medicine",
"city": "Miami",
"state": "Flo... | null | {
"compound": "Arimoclomol",
"targeting_mechanism": "Arimoclomol acts as a heat shock response inducer to enhance clearance of misfolded proteins, particularly TDP-43, and improve protein homeostasis in motor neurons.",
"targeting_mechanism_pmid": "26936937",
"animal_results": "unknown",
"animal_results_pmid"... | ||
NCT06700304 | CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices | NA | RECRUITING | INTERVENTIONAL | false | Neuralink Corp | The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, ... | [
{
"type": "DEVICE",
"name": "N1 Implant"
},
{
"type": "DEVICE",
"name": "R1 Robot"
}
] | 2024-11-20 | https://clinicaltrials.gov/study/NCT06700304 | [] | [
{
"facility": "University Health Network",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "RECRUITING",
"lat": 43.70643,
"lon": -79.39864
}
] | (877) 398-4465 | clinical-team-ct@neuralink.com | null | {
"compound": "N1 Implant",
"targeting_mechanism": "The N1 Implant is a wireless brain-computer interface device that records neural signals to enable direct control of external devices for patients with motor paralysis.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",... |
NCT02286011 | Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Red de Terapia Celular | The purpose of this study is to evaluate the safety of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis by a prospective, single-center, randomized, parallel, double-blind, placebo-controlled phase I clinical trial. | [
{
"type": "BIOLOGICAL",
"name": "MNC (Mononuclear cells)"
},
{
"type": "OTHER",
"name": "Saline"
}
] | 2014-11 | https://clinicaltrials.gov/study/NCT02286011 | [
"neuroprotection"
] | [
{
"facility": "Clinical Universitary Hospital Virgen de la Arrixaca",
"city": "El Palmar",
"state": "Murcia",
"country": "Spain",
"status": "",
"lat": 37.93939,
"lon": -1.16095
}
] | null | {
"compound": "MNC (Mononuclear cells)",
"targeting_mechanism": "Autologous bone marrow-derived mononuclear cells differentiate into supportive glial cells and produce neurotrophic factors and anti-inflammatory cytokines to protect degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"animal_re... | ||
NCT02039401 | Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Helixmith Co., Ltd. | The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "VM202"
}
] | 2014-03-11 | https://clinicaltrials.gov/study/NCT02039401 | [
"angiogenesis"
] | [
{
"facility": "Northwestern University",
"city": "Chicago",
"state": "Illinois",
"country": "United States",
"status": "",
"lat": 41.85003,
"lon": -87.65005
}
] | null | {
"compound": "VM202",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05819931 | Breathing With Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University Hospital, Toulouse | The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak expiratory flow on cough (PEFC) measurements. The evolution of their PEFC is monitored to see if the curative management can have a positive impact ... | [
{
"type": "DEVICE",
"name": "Mechanical In-Exsufflator treatment"
}
] | 2023-08-29 | https://clinicaltrials.gov/study/NCT05819931 | [] | [
{
"facility": "SLA Center - Purpan University Hospital Toulouse, FRANCE",
"city": "Toulouse",
"state": "Occitanie",
"country": "France",
"status": "RECRUITING",
"lat": 43.60426,
"lon": 1.44367
}
] | +33561775570 | lagarde.t@chu-toulouse.fr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00231140 | Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Charite University, Berlin, Germany | Neuroinflammation has recently emerged as a significant contributor to motor neuron damage. ALS tissue is characterized by inflammatory changes that are observed in both sporadic and familial ALS and in the ALS superoxide dismutase 1 (SOD1) transgenic mouse model. They include an accumulation of large numbers of activa... | [
{
"type": "DRUG",
"name": "Thalidomide (drug)"
}
] | 2005-12 | https://clinicaltrials.gov/study/NCT00231140 | [
"neuroinflammation"
] | [
{
"facility": "Charite University Hospital, Berlin, Germany",
"city": "Berlin",
"state": "State of Berlin",
"country": "Germany",
"status": "",
"lat": 52.52437,
"lon": 13.41053
}
] | null | {
"compound": "Thalidomide",
"targeting_mechanism": "Reduces tumor necrosis factor-α (TNF-α) and modulates neuroinflammatory responses in ALS through inhibition of TNF-R1 signaling and suppression of activated microglia and astrocytes.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_res... | ||
NCT05866926 | Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis | PHASE3 | TERMINATED | INTERVENTIONAL | false | Ferrer Internacional S.A. | A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis | [
{
"type": "DRUG",
"name": "FAB122"
}
] | 2023-03-06 | https://clinicaltrials.gov/study/NCT05866926 | [
"fab122"
] | [
{
"facility": "Hospital Universitari de Bellvitge",
"city": "Barcelona",
"state": "",
"country": "Spain",
"status": "",
"lat": 41.38879,
"lon": 2.15899
}
] | null | {
"compound": "FAB122",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03520517 | Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Biohaven Pharmaceuticals, Inc. | Phase 1, open-label study of BHV-0223 in ALS. | [
{
"type": "DRUG",
"name": "BHV-0223"
}
] | 2018-02-02 | https://clinicaltrials.gov/study/NCT03520517 | [
"bhv_0223"
] | [
{
"facility": "Holy Cross Neuroscience Research Institute",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.12231,
"lon": -80.14338
},
{
"facility": "Somnos/Neurology Associates Clinical Research",
"city": "Lincoln",
"sta... | null | {
"compound": "BHV-0223",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03186040 | Open-label Clinical Trial of Lacosamide in ALS | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Chiba University | Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Lacosamide"
}
] | 2017-07-13 | https://clinicaltrials.gov/study/NCT03186040 | [
"lacosamide"
] | [
{
"facility": "Chiba University Hospital",
"city": "Chiba",
"state": "",
"country": "Japan",
"status": "",
"lat": 35.6,
"lon": 140.11667
}
] | null | {
"compound": "Lacosamide",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00069186 | Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis | PHASE3 | UNKNOWN | INTERVENTIONAL | false | The Avicena Group | The purpose of this study is to determine whether nine months of administration of creatine monohydrate results in an increase in muscle strength in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Creatine Monohydrate"
}
] | 2003-06 | https://clinicaltrials.gov/study/NCT00069186 | [
"oxidative_stress"
] | [
{
"facility": "University of California, San Francisco",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "University of Kansas",
"city": "Kansas City",
"state": "Kansas",
"co... | null | {
"compound": "Creatine Monohydrate",
"targeting_mechanism": "Creatine enhances cellular energy metabolism and reduces oxidative stress in motor neurons.",
"targeting_mechanism_pmid": "34198557",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_... | ||
NCT02238626 | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | MediciNova | This is a single center, randomized, double-blind, placebo-controlled, 6-month study designed to evaluate the safety, tolerability and clinical responsiveness of MN-166/ibudilast (60 mg/day) when administered as an adjunct to riluzole (100 mg/day) in 60 subjects with ALS.
This study will consist of two treatment arms,... | [
{
"type": "DRUG",
"name": "Placebo (for MN-166)"
},
{
"type": "DRUG",
"name": "MN-166"
},
{
"type": "DRUG",
"name": "riluzole"
}
] | 2014-09 | https://clinicaltrials.gov/study/NCT02238626 | [
"neuroinflammation"
] | [
{
"facility": "Carolinas Healthcare System, Dept. of Neurology",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.22709,
"lon": -80.84313
}
] | null | {
"compound": "MN-166 (Ibudilast)",
"targeting_mechanism": "Ibudilast reduces neuroinflammation by inhibiting microglia and astrocyte activation in the CNS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "AAV9-treated SOD1G93A mice showed delayed paralysis onset and extended survival compared to un... | ||
NCT00958048 | Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | National Taiwan University Hospital | Specific aims:
Aim 1. To determine the incidence of hypoventilation in Amyotrophic Lateral Sclerosis (ALS) patients.
Aim 2. To identify the clinical characteristics and risk factors associated .
Aim 3. To determine the effect of early intervention with nocturnal NIV on the prognosis of ALS patients. | [
{
"type": "DEVICE",
"name": "non-invasive ventilation"
}
] | 2009-01 | https://clinicaltrials.gov/study/NCT00958048 | [] | [
{
"facility": "Peilin Lee",
"city": "Taipei",
"state": "",
"country": "Taiwan",
"status": "",
"lat": 25.05306,
"lon": 121.52639
}
] | null | {
"compound": "non-invasive ventilation",
"targeting_mechanism": "Non-invasive ventilation (NIV) provides mechanical respiratory support to compensate for progressive motor neuron loss affecting the diaphragm and accessory respiratory muscles.",
"targeting_mechanism_pmid": "29990478",
"animal_results": "unknown... | ||
NCT00298597 | Influence of G-CSF and EPO on Associative Learning and Motor Skills | PHASE2 | COMPLETED | INTERVENTIONAL | false | University Hospital Muenster | In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. The study hypothesis is that G-CSF and EPO improve associa... | [
{
"type": "DRUG",
"name": "granulocyte - colony stimulating factor (G-CSF)"
},
{
"type": "DRUG",
"name": "erythropoetin (EPO)"
}
] | 2006-03 | https://clinicaltrials.gov/study/NCT00298597 | [
"g_csf",
"epo"
] | [
{
"facility": "Department of neurology, University Hospital of Muenster",
"city": "Münster",
"state": "North Rhine-Westphalia",
"country": "Germany",
"status": "",
"lat": 51.96236,
"lon": 7.62571
}
] | null | {
"compound": "granulocyte-colony stimulating factor (G-CSF) and erythropoietin (EPO)",
"targeting_mechanism": "G-CSF and EPO promote hematopoiesis and neuronal protection through neurotrophic and neuroprotective mechanisms to support motor neuron function.",
"targeting_mechanism_pmid": "",
"animal_results": "u... | ||
NCT05035823 | COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis | NA | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Synchron Medical, Inc. | The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility.
The MNP is a type of implantable brain computer inte... | [
{
"type": "DEVICE",
"name": "Motor Neuroprosthesis (MNP)"
}
] | 2022-04-27 | https://clinicaltrials.gov/study/NCT05035823 | [] | [
{
"facility": "University at Buffalo Neurosurgery (UBNS)",
"city": "Buffalo",
"state": "New York",
"country": "United States",
"status": "",
"lat": 42.88645,
"lon": -78.87837
},
{
"facility": "Mount Sinai Health System",
"city": "New York",
"state": "New York",
"count... | null | {
"compound": "Motor Neuroprosthesis (MNP)",
"targeting_mechanism": "The implantable brain–computer interface device bypasses dysfunctional motor neurons by directly translating neural signals from the motor cortex to control external digital devices.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown... | ||
NCT07138014 | FHND1002 for ALS Treatment: Phase 2 | PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | This is a Phase II clinical trial evaluating the effectiveness and safety of an investigational drug, FHND1002 granules, in adults with Amyotrophic Lateral Sclerosis (ALS).
The main goals are:
To determine if FHND1002 can slow the progression of ALS compared to a placebo.
To assess the safety and tolerability of two... | [
{
"type": "DRUG",
"name": "FHND1002 100mg"
},
{
"type": "DRUG",
"name": "FHND1002 200mg"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-10-01 | https://clinicaltrials.gov/study/NCT07138014 | [] | [] | 010-82265159 | dsfan@sina.com | null | {
"compound": "FHND1002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | PHASE2 | RECRUITING | INTERVENTIONAL | false | Reunion Neuroscience Inc | The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), ... | [
{
"type": "DRUG",
"name": "RE104 for Injection"
}
] | 2025-07-30 | https://clinicaltrials.gov/study/NCT07002034 | [] | [
{
"facility": "UAB, Psychiatry and Behavioral Neurology",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "RECRUITING",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "University of Arizona",
"city": "Tucson",
"state": "Arizona",
"c... | 1-888-880-REUN | info@reunionneuro.com | null | {
"compound": "RE104",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01363401 | Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Corestemchemon, Inc. | The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS.
This study consists of 2 steps. First step is a safety study of the intrathecal(IT) injection of "HYNR-CS inj" in 8 patients... | [
{
"type": "BIOLOGICAL",
"name": "HYNR-CS inj"
},
{
"type": "OTHER",
"name": "Control group"
}
] | 2011-02 | https://clinicaltrials.gov/study/NCT01363401 | [
"stem_cell_therapy"
] | [
{
"facility": "Hanyang University Hospital",
"city": "Seoul",
"state": "",
"country": "South Korea",
"status": "",
"lat": 37.566,
"lon": 126.9784
}
] | null | {
"compound": "HYNR-CS inj (autologous bone marrow-derived stem cells)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03811301 | [BrainConnexion] - Neurodevice Phase I Trial | NA | UNKNOWN | INTERVENTIONAL | false | National Neuroscience Institute | This study aims to evaluate the safety of a wireless implantable neurodevice microsystem in tetraplegic patients, as well as the efficacy of the electrodes for long-term recording of neural activities and the successful control of an external device. | [
{
"type": "DEVICE",
"name": "BrainConnexion"
}
] | 2017-11-21 | https://clinicaltrials.gov/study/NCT03811301 | [] | [
{
"facility": "National Neuroscience Institute",
"city": "Singapore",
"state": "",
"country": "Singapore",
"status": "",
"lat": 1.28967,
"lon": 103.85007
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07616050 | Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Marta Mondellini | The purpose of this clinical study is to evaluate the feasibility, usability, and motivational impact of VirtualPark, a virtual reality-based dual-task rehabilitation system, in adults with neurological and age-related conditions.
VirtualPark is a virtual reality application designed to deliver cognitive exercises dur... | [
{
"type": "DEVICE",
"name": "Dual-task training with Virtual Reality"
},
{
"type": "DEVICE",
"name": "Cycling training"
}
] | 2026-06 | https://clinicaltrials.gov/study/NCT07616050 | [] | [
{
"facility": "Istituti a Carattere Scientifico Maugeri Bari",
"city": "Bari",
"state": "Bari",
"country": "Italy",
"status": "",
"lat": 41.12066,
"lon": 16.86982
},
{
"facility": "Istituti a Carattere Scientifico Maugeri Telese",
"city": "Telese Terme",
"state": "Beneven... | 0039.0341.2350202 | marta.mondellini@cnr.it | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06714396 | A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | QurAlis Corporation | This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants. The study will also assess safety and tolerability in participants receiving either QRL-101 or placebo. | [
{
"type": "DRUG",
"name": "QRL-101"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2024-11-11 | https://clinicaltrials.gov/study/NCT06714396 | [] | [
{
"facility": "Universitair Medisch Centrum Utrecht",
"city": "Utrecht",
"state": "Netherlands",
"country": "Netherlands",
"status": "",
"lat": 52.09083,
"lon": 5.12222
}
] | null | {
"compound": "QRL-101",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04695210 | Virtual Peer-to-peer Support Programme for Carers of MND | NA | COMPLETED | INTERVENTIONAL | false | King's College London | Background/scope There is growing recognition that family caregiving is a serious public health issue requiring supportive interventions. Family caregivers play an essential role in sustaining a stable environment enabling individuals with motor neurone disease (MND) that are technology dependent to live at home. The f... | [
{
"type": "BEHAVIORAL",
"name": "Virtual peer-to-peer support"
}
] | 2022-06-07 | https://clinicaltrials.gov/study/NCT04695210 | [] | [
{
"facility": "Bedfordshire Hospitals NHS Foundation Trust",
"city": "Bedford",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 52.13459,
"lon": -0.46632
},
{
"facility": "Airedale NHS Foundation Trust",
"city": "Bradford",
"state": "",
"country": "Unit... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07077668 | Extended Study of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation | EARLY_PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Beijing Tiantan Hospital | This study primarily evaluates the safety, tolerability, and efficacy of RAG - 17 in adult ALS patients with SOD1 - mutated genes in the real - world setting. | [
{
"type": "DRUG",
"name": "A sterile aqueous solution of RAG - 17 preparation (sodium salt)"
}
] | 2025-07 | https://clinicaltrials.gov/study/NCT07077668 | [
"SOD1"
] | [] | 13911666571 | yilong528@gmail.com | null | {
"compound": "RAG-17",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07071935 | A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS) | PHASE2 | RECRUITING | INTERVENTIONAL | false | University of Pennsylvania | Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by ... | [
{
"type": "DEVICE",
"name": "Non-invasive ventilation"
}
] | 2026-06-11 | https://clinicaltrials.gov/study/NCT07071935 | [] | [
{
"facility": "Penn State Hershey ALS Clinic",
"city": "Hershey",
"state": "Pennsylvania",
"country": "United States",
"status": "RECRUITING",
"lat": 40.28592,
"lon": -76.65025
},
{
"facility": "Penn Comprehensive ALS Center at Pennsylvania Hospital",
"city": "Philadelphia",
... | 215-829-3053 | jason.ackrivo@pennmedicine.upenn.edu | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT03981536 | A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | UNKNOWN | INTERVENTIONAL | false | AL-S Pharma | Single ascending doses of AP-101 will be administered by intravenous (IV) infusion | [
{
"type": "DRUG",
"name": "AP-101"
}
] | 2019-10-10 | https://clinicaltrials.gov/study/NCT03981536 | [] | [
{
"facility": "London Health Sciences Centre, University Hospital",
"city": "London",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 42.98339,
"lon": -81.23304
},
{
"facility": "Sunnybrook Health Sciences Centre, Toronto",
"city": "Toronto",
"state": "Ontar... | null | {
"compound": "AP-101",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03293394 | Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor ... | [
{
"type": "DEVICE",
"name": "Anodal bilateral motor cortex and cathodal spinal tDCS"
},
{
"type": "DEVICE",
"name": "Sham bilateral motor cortex and sham spinal tDCS"
}
] | 2017-10-02 | https://clinicaltrials.gov/study/NCT03293394 | [
"motor_cortex_excitability"
] | [
{
"facility": "AO Spedali Civili",
"city": "Brescia",
"state": "BS",
"country": "Italy",
"status": "",
"lat": 45.53558,
"lon": 10.21472
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation technique applied to motor cortex and spinal cord to modulate neuronal activity.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurp... | ||
NCT01254539 | Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | The purpose of this clinical trial is to assess the feasibility and the security of the intraspinal and intrathecal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients. | [
{
"type": "PROCEDURE",
"name": "Laminectomy and bone marrow stem cells transplantation"
},
{
"type": "PROCEDURE",
"name": "Intrathecal infusion of autologous bone marrow stem cells"
},
{
"type": "PROCEDURE",
"name": "Intrathecal infusion of placebo (saline solution)."
}
] | 2010-10 | https://clinicaltrials.gov/study/NCT01254539 | [
"neuroprotection_and_neuroregeneration_via_stem_cell_transplantation"
] | [
{
"facility": "Hospital Universitario Virgen de la Arrixaca",
"city": "El Palmar",
"state": "Murcia",
"country": "Spain",
"status": "",
"lat": 37.93939,
"lon": -1.16095
}
] | null | {
"compound": "Autologous bone marrow stem cells",
"targeting_mechanism": "Stem cells differentiate into support cells such as astrocytes and oligodendrocytes, which may benefit degenerating motor neurons by producing growth factors and anti-inflammatory cytokines, providing nutrients and buffering excessive glutam... | ||
NCT06889857 | Safety and Efficacy of Intravenous Administration of SHED-CM for ALS | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Hitonowa Medical | This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator. | [
{
"type": "BIOLOGICAL",
"name": "The study drug is SHED-CM manufactured by U-Factor"
}
] | 2024-04-05 | https://clinicaltrials.gov/study/NCT06889857 | [
"neuroprotection_via_stem_cell_secretome"
] | [
{
"facility": "Hitonowa Medical",
"city": "Chiyoda City",
"state": "Tokyo",
"country": "Japan",
"status": "",
"lat": 35.68449,
"lon": 139.75056
}
] | null | {
"compound": "SHED-CM (Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01825551 | The Effect of GCSF in the Treatment of ALS Patients | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Tehran University of Medical Sciences | The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients. | [
{
"type": "DRUG",
"name": "Granulocyte Colony Stimulating Factor"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2012-11 | https://clinicaltrials.gov/study/NCT01825551 | [
"monocyte_macrophage_differentiation_and_neuroprotection"
] | [
{
"facility": "Iranian Neurology Research Center of Tehran University of Medical Sciences",
"city": "Tehran",
"state": "Tehran Province",
"country": "Iran",
"status": "",
"lat": 35.69439,
"lon": 51.42151
}
] | null | {
"compound": "Granulocyte Colony Stimulating Factor (GCSF)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05979688 | Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University of Alabama at Birmingham | The aim of this study is to understand how well a 6-week virtual yogic breathing exercise program (YBEP) will improve breathing, speech, and emotional well-being in people with amyotrophic lateral sclerosis (ALS). | [
{
"type": "BEHAVIORAL",
"name": "yogic breathing exercise"
}
] | 2023-11-01 | https://clinicaltrials.gov/study/NCT05979688 | [] | [
{
"facility": "University of Alabama at Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "",
"lat": 33.52066,
"lon": -86.80249
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "Yogic breathing exercise is a behavioral intervention designed to improve respiratory muscle function and ventilation in ALS patients.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed... | ||
NCT04997954 | EMERALD TRIAL Open Label Extension Study | PHASE4 | UNKNOWN | INTERVENTIONAL | false | Gold Coast Hospital and Health Service | EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied. EMERALD OLE aims to establish data on the prolonged used of the study drug product.
All participants who completed the EMERALD trial will be offered to enter... | [
{
"type": "DRUG",
"name": "MediCabilis CBD oil"
}
] | 2021-05-17 | https://clinicaltrials.gov/study/NCT04997954 | [
"cb1_and_cb2_receptors"
] | [
{
"facility": "Gold Coast Hospital and Health Service",
"city": "Gold Coast",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -28.00029,
"lon": 153.43088
}
] | null | {
"compound": "MediCabilis CBD oil",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00561366 | A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | CytRx | Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1) transgenic mouse model of ALS. Furthermore, it has been demonstrated to have neuropro... | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Arimoclomol"
}
] | https://clinicaltrials.gov/study/NCT00561366 | [
"heat_shock_proteins_molecular_chaperones"
] | [
{
"facility": "University of California Los Angeles - Tier 2 Site",
"city": "Pacific Palisades",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.04806,
"lon": -118.52647
},
{
"facility": "University of California - San Francisco - Tier 2 Site",
"cit... | null | {
"compound": "Arimoclomol",
"targeting_mechanism": "Arimoclomol upregulates molecular chaperones in cells under stress.",
"targeting_mechanism_pmid": "",
"animal_results": "Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1... | |||
NCT00107770 | Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | US Department of Veterans Affairs | The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects. | [
{
"type": "DRUG",
"name": "sodium phenylbutyrate"
}
] | 2005-04 | https://clinicaltrials.gov/study/NCT00107770 | [
"protein_aggregation_and_cellular_stress"
] | [
{
"facility": "VA Medical Center, Iowa City",
"city": "Iowa City",
"state": "Iowa",
"country": "United States",
"status": "",
"lat": 41.66113,
"lon": -91.53017
},
{
"facility": "VA Medical Center, Lexington",
"city": "Lexington",
"state": "Kentucky",
"country": "Unite... | null | {
"compound": "sodium phenylbutyrate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04947436 | ALS and Airway Clearance (ALSAC) Therapy | NA | COMPLETED | INTERVENTIONAL | false | The University of Texas Health Science Center at San Antonio | Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE. The study period will be six months and include three clinic visits, baseline and follow-up visits at... | [
{
"type": "DEVICE",
"name": "High Frequency Chest Wall Oscillation"
},
{
"type": "DEVICE",
"name": "Mechanical insufflation/exsufflation"
}
] | 2012-01-25 | https://clinicaltrials.gov/study/NCT04947436 | [] | [
{
"facility": "University of Texas Health San Antonio",
"city": "San Antonio",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.42412,
"lon": -98.49363
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04326283 | Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Genuv Inc. | The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "Trametinib (0.5 mg)"
},
{
"type": "DRUG",
"name": "Trametinib (1 mg)"
},
{
"type": "DRUG",
"name": "Riluzole (100 mg)"
}
] | 2020-04-02 | https://clinicaltrials.gov/study/NCT04326283 | [
"mapk_erk_pathway"
] | [
{
"facility": "Inje University Busan Paik Hospital",
"city": "Busan",
"state": "",
"country": "South Korea",
"status": "",
"lat": 35.10168,
"lon": 129.03004
},
{
"facility": "Asan Medical Center",
"city": "Seoul",
"state": "",
"country": "South Korea",
"status": "... | null | {
"compound": "Trametinib",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00875446 | First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | GlaxoSmithKline | The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS).
The drug works by inhibiting the protein that prevents nerve growth.
This will be the first time the drug will be given to man. The trial is expected to i... | [
{
"type": "DRUG",
"name": "PLACEBO"
},
{
"type": "DRUG",
"name": "GSK1223249"
}
] | 2009-05-13 | https://clinicaltrials.gov/study/NCT00875446 | [
"nerve_growth_factor_pathway"
] | [
{
"facility": "GSK Investigational Site",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
},
{
"facility": "GSK Investigational Site",
"city": "New York",
"state": "New York",
"country": "United Sta... | null | {
"compound": "GSK1223249",
"targeting_mechanism": "Inhibits the protein that prevents nerve growth.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06891716 | [18F]ACI-19626 PET in TDP-43 Proteinopathies | EARLY_PHASE1 | RECRUITING | INTERVENTIONAL | false | AC Immune SA | The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 \[involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic lateral sclerosis (ALS)\] using a new positron emission tomography (PET) tracer called \[18F... | [
{
"type": "OTHER",
"name": "[18F]ACI-19626"
}
] | 2025-01-21 | https://clinicaltrials.gov/study/NCT06891716 | [
"TARDBP"
] | [
{
"facility": "Amsterdam UMC",
"city": "Amsterdam",
"state": "",
"country": "Netherlands",
"status": "RECRUITING",
"lat": 52.37403,
"lon": 4.88969
}
] | null | {
"compound": "[18F]ACI-19626",
"targeting_mechanism": "A positron emission tomography (PET) tracer designed to measure the accumulation of pathological protein TDP-43.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurpose... | ||
NCT07080801 | Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations | EARLY_PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Beijing Tiantan Hospital | Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes. In Asia, mutations in the FUS gene are relatively common among early-onset familial ALS patients. R... | [
{
"type": "DRUG",
"name": "RAG-21"
}
] | 2025-08 | https://clinicaltrials.gov/study/NCT07080801 | [
"FUS"
] | [] | 13521588395 | liuxinru0826@163.com | null | {
"compound": "RAG-21",
"targeting_mechanism": "A small interfering RNA that reduces the levels of toxic FUS protein in FUS-mutant ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT01777646 | Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Brainstorm-Cell Therapeutics | The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral sclerosis (ALS). | [
{
"type": "BIOLOGICAL",
"name": "MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF"
}
] | 2012-12 | https://clinicaltrials.gov/study/NCT01777646 | [
"neurotrophic_factors"
] | [
{
"facility": "Hadassah Medical Organization",
"city": "Jerusalem",
"state": "",
"country": "Israel",
"status": "",
"lat": 31.76904,
"lon": 35.21633
}
] | null | {
"compound": "MSC-NTF cells (autologous mesenchymal bone marrow stromal cells secreting neurotrophic factors)",
"targeting_mechanism": "Autologous mesenchymal stromal cells engineered to secrete neurotrophic factors that provide neuroprotective support to degenerating motor neurons.",
"targeting_mechanism_pmid":... | ||
NCT05595850 | A Mindful Community for People With ALS and Their Primary Caregivers | NA | COMPLETED | INTERVENTIONAL | false | Harvard University | The psychological impact of ALS on patients and caregivers is high, significantly affecting their quality of life (QOL). Despite this impact, there is not much research about psychological interventions that could reduce psychological distress and improve QOL.
The efficacy of mindfulness-based treatments for the impro... | [
{
"type": "BEHAVIORAL",
"name": "Mindfulness"
},
{
"type": "BEHAVIORAL",
"name": "Mindful Learning"
}
] | 2020-05-15 | https://clinicaltrials.gov/study/NCT05595850 | [] | [
{
"facility": "Harvard University",
"city": "Cambridge",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.3751,
"lon": -71.10561
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04809675 | Effectiveness of Two Oral Appliances for Managing Oral Self-biting Injuries in Patients With ALS | NA | UNKNOWN | INTERVENTIONAL | false | University of Barcelona | This study assesses to determine the most effective type of device on the degree of satisfaction of patients with amyotrophic lateral sclerosis for managing oral self-biting injuries. Thirty-one patients with amyotrophic lateral sclerosis will wear two devices, a hard occlusal splint (HOS) and a flexible customized mou... | [
{
"type": "DEVICE",
"name": "Hard occlusal splint"
},
{
"type": "DEVICE",
"name": "Flexible customized mouthguard"
}
] | 2019-11-29 | https://clinicaltrials.gov/study/NCT04809675 | [] | [
{
"facility": "Nina Riera-Punet",
"city": "Barcelona",
"state": "L'Hospitalet de Llobregat",
"country": "Spain",
"status": "RECRUITING",
"lat": 41.38879,
"lon": 2.15899
}
] | 934035555 | ninariera@ub.edu | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02424669 | Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron diseases. It is considered as a rare disease with a prevalence of about 8 per 100,000 persons. Initiating in mid-life by progressive paralysis, it evolves rapidly into a generalized muscle wasting that leads irrevocably to death within 2 or 5 years of ... | [
{
"type": "OTHER",
"name": "ALS Functional rating Scale-revised (ALS FRS-R)"
},
{
"type": "OTHER",
"name": "slow vital capacity"
},
{
"type": "OTHER",
"name": "Blood sample"
},
{
"type": "OTHER",
"name": "Cerebrospinal Fluid (CSF) sample"
}
] | 2015-05 | https://clinicaltrials.gov/study/NCT02424669 | [
"neuroinflammation"
] | [
{
"facility": "Assistance Publique Hôpitaux de Marseille",
"city": "Marseille",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 43.29695,
"lon": 5.38107
}
] | joelle.micallef@ap-hm.fr | null | {
"compound": "unknown",
"targeting_mechanism": "Investigating neuroinflammation as a mechanism in ALS pathogenesis and therapeutic target.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |
NCT01521728 | Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Johns Hopkins University | The first questions asked by patients with a new diagnosis of Amyotrophic Lateral Sclerosis (ALS) often include: "Does exercise help slow the progression of the disease?", "Is there any harm in exercising?", or "What type of exercise (endurance or resistance) is most appropriate?" At this time, however, there is a lack... | [
{
"type": "OTHER",
"name": "Resistance Exercise"
},
{
"type": "OTHER",
"name": "Endurance Exercise"
},
{
"type": "OTHER",
"name": "Stretching/Range-of-Motion"
}
] | 2012-01 | https://clinicaltrials.gov/study/NCT01521728 | [] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"country": "U... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04499963 | Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Richard Bedlack, M.D., Ph.D. | This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group. | [
{
"type": "DRUG",
"name": "Theracurmin HP"
}
] | 2020-08-28 | https://clinicaltrials.gov/study/NCT04499963 | [
"curcumin"
] | [
{
"facility": "Duke University Medical Center",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
}
] | null | {
"compound": "Theracurmin HP",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02881489 | Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | University of Warmia and Mazury | The goal of this study is to investigate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells administration in the individuals with diagnosed amyotrophic lateral sclerosis. | [
{
"type": "OTHER",
"name": "Biological: Cell-based therapy"
}
] | 2015-11 | https://clinicaltrials.gov/study/NCT02881489 | [] | [] | null | {
"compound": "Autologous bone marrow mesenchymal stem cells",
"targeting_mechanism": "Mesenchymal stem cells differentiate into support cells that produce growth factors and anti-inflammatory cytokines to benefit degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"animal_results": "Preclinic... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.